BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

LifeScience

Kazia Therapeutics Partners with QIMR Berghofer to Develop First-in-Class PD-L1 Degrader NDL2

Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, announced an exclusive collaboration and in-licensing agreem...

October 09, 2025 | News

Asia-Pacific Takes the Lead in Global Biopharma Resilience: Cytiva’s 2025 Index Highlights Regional Rise Amid Global Slowdown

The 2025 Global Biopharma Index released by Cytiva, a Danaher company, reveals that while the global biopharma ecosystem has experienced a modest decline i...

October 08, 2025 | Analysis

Made Scientific and Streamline Bio Validate AI-Driven Robotic Platform for Cell Therapy Manufacturing

Made Scientific, a leading clinical and commercial-enabling cell therapy contract development and manufacturing organization (CDMO), and Streamline Bio, a ...

October 07, 2025 | News

Wasatch BioLabs Expands Long-Read Sequencing Portfolio with Oxford Nanopore Research Assays

Wasatch BioLabs (WBL), a Renew Biotechnologies subsidiary, and the largest U.S. sequencing service provider dedicated exclusively to long-read se...

October 07, 2025 | News

AbbVie’s BOTOX® Achieves Primary and Secondary Endpoints in Phase 2 ELATE Trial for Essential Tremor

OnabotulinumtoxinA (BOTOX®) met the primary endpoint in the Phase 2 trial, demonstrating a statistically significant improvement ...

October 07, 2025 | News

Turning Signals into Cures: The Big Data Blueprint for Cell Therapy Factories

Cell therapy manufacturing is entering a data-driven era, as the industry grapples with complex production processes, high costs, and the need for personal...

October 07, 2025 | Analysis

Takeda Steps Back from Cell & Gene Therapy to Refocus on Predictable Growth

Takeda Pharmaceutical, one of the world’s most globalised pharma companies, has confirmed it will step away from in-house development of its cell and...

October 05, 2025 | News

Nanyang Biologics to Go Public Through Business Combination with RF Acquisition Corp II Valued at 1.5 Billion USD

Nanyang Biologics Pte. Ltd., together with its subsidiaries (collectively, the "Company", "we" or "NYB"), offers a comprehensive drug discovery platform ...

October 03, 2025 | News

Celltrion Launches AVTOZMA IV FDA Approved Tocilizumab Biosimilar in United States

The AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation was approved in January 2025 by the FDA to treat the same conditions as t...

October 03, 2025 | News

JCR Pharmaceuticals Grants Menagen Exclusive Rights to Commercialise Fabry Therapy Across MENAT Region

JCR Pharmaceuticals Co., Ltd. a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, announced ...

October 03, 2025 | News

Redefining Cancer Care in Southeast Asia: Siemens Healthineers’ Fabrice Leguet on Turning Awareness into Action

Cancer care in Southeast Asia stands at a critical crossroads. While awareness of early detection is high, the translation into meaningful action remains p...

October 01, 2025 | Interaction | By arcilla.fran@biopharmaapac.com

WuXi XDC Co-Hosts 2025 BPD Singapore Summit Showcasing Innovation in Bioconjugates and Global Biopharma Collaboration

The 2025 BPD (Biopharmaceutical Bioprocess Development) Singapore Summit, which co-hosted by WuXi XDC (Stock Code: 2268.HK), was successfully conclude...

September 30, 2025 | News

Daiichi Sankyo and AstraZeneca’s ENHERTU delivers second positive phase 3 win in HER2 positive early breast cancer

Second positive phase 3 trial of Daiichi Sankyo and AstraZeneca’s ENHERTU in HER2 positive early breast cancer reinforces its potential to become...

September 30, 2025 | News

Catalent Opens New Global Headquarters in Tampa to Shape the Future of Biopharma Innovation

Relocation reflects a strategic expansion in Florida alongside long-standing manufacturing facility in nearby St. Petersburg New ...

September 29, 2025 | News

Stay Connected